Cover |
Jun. 23, 2025 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Amendment Flag | true |
| Amendment Description | As previously disclosed in its Current Report on Form 8-K filed with the Securities and Exchange Commission on June 23, 2025 (the “Original Form 8-K”), on June 18, 2025 (the “Closing Date”), Shineco Life Science Group Hong Kong Co., Limited (“Shineco Life Science”), a subsidiary of Shineco, Inc. (the “Company”), closed an acquisition of 51% of the equity interests in InfiniClone Limited, a company limited by shares incorporated in Hong Kong (“InfiniClone”), pursuant to the share purchase agreement (the “SPA”) dated April 22, 2025 with Dr. Lim Kah Meng, the sole shareholder of InfiniClone (the “Seller”). On or prior to the Closing Date, the closing conditions as set forth in the SPA were satisfied or otherwise waived by the parties thereto, and the Seller has transferred 51% of the equity interests in InfiniClone to Shineco Life Science; therefore, InfiniClone became a direct subsidiary of Shineco Life Science. |
| Document Period End Date | Jun. 23, 2025 |
| Entity File Number | 001-37776 |
| Entity Registrant Name | SHINECO, INC. |
| Entity Central Index Key | 0001300734 |
| Entity Tax Identification Number | 52-2175898 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | Room 1707, Block D, Modern City SOHO |
| Entity Address, Address Line Two | No. 88, Jianguo Road |
| Entity Address, Address Line Three | Chaoyang District |
| Entity Address, City or Town | Beijing |
| Entity Address, Country | CN |
| Entity Address, Postal Zip Code | 100022 |
| City Area Code | (+86) |
| Local Phone Number | 10-87227366 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock |
| Trading Symbol | SISI |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |